Fig. 2From: New-onset graves’ disease after the initiation of nivolumab therapy for gastric cancer: a case report99mTc-pertechnetate scintigraphy showing elevated, bilateral, and diffuse uptake of the radioactive tracer (4.7%)Back to article page